Brain tumors are among the most serious cancers that can have a negative impact on a person's quality of life. The magnetic resonance imaging (MRI) analysis detects abnormal cell growth in the skull. Recently, machine learning models such as artificial neural networks have been used to detect brain tumors more quickly. To classify brain tumors, this research introduces the Y-net, a new convolutional neural network (CNN) based on the convolutional U-net architecture. We apply a NADE concatenation method in pre-processing the MR images for enhanced Y-net performance. We put our approach to the test using two MRI datasets of brain tumors. The first dataset contains three different types of brain tumors, while the second dataset includes a separate category for healthy brains. We show that our model is resistant to white noise and can obtain excellent classification accuracy with a limited number of medical images.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/2057-1976/ac107b | DOI Listing |
ACS Nano
January 2025
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
Glioblastoma multiforme (GBM), particularly the deep-seated tumor where surgical removal is not feasible, poses great challenges for clinical treatments due to complicated biological barriers and the risk of damaging healthy brain tissue. Here, we hierarchically engineer a self-adaptive nanoplatform (SAN) that overcomes delivery barriers by dynamically adjusting its structure, surface charge, particle size, and targeting moieties to precisely distinguish between tumor and parenchyma cells. We further devise a AN-uided ntuitive and recision ntervention (SGIPi) strategy which obviates the need for sophisticated facilities, skilled operations, and real-time magnetic resonance imaging (MRI) guidance required by current MRI-guided laser or ultrasound interventions.
View Article and Find Full Text PDFCNS Neurosci Ther
January 2025
Jiujiang Clinical Precision Medicine Research Center, Jiujiang, Jiangxi, China.
Background: Adenosine deaminase action on RNA 1 (ADAR1) can convert the adenosine in double-stranded RNA (dsRNA) molecules into inosine in a process known as A-to-I RNA editing. ADAR1 regulates gene expression output by interacting with RNA and other proteins; plays important roles in development, including growth; and is linked to innate immunity, tumors, and central nervous system (CNS) diseases.
Results: In recent years, the role of ADAR1 in tumors has been widely discussed, but its role in CNS diseases has not been reviewed.
Sci Rep
January 2025
Department of Electronics, Information and Communication Engineering, Kangwon National University, Samcheok, Republic of Korea.
Detecting brain tumours (BT) early improves treatment possibilities and increases patient survival rates. Magnetic resonance imaging (MRI) scanning offers more comprehensive information, such as better contrast and clarity, than any alternative scanning process. Manually separating BTs from several MRI images gathered in medical practice for cancer analysis is challenging and time-consuming.
View Article and Find Full Text PDFNPJ Precis Oncol
January 2025
Athinoula A. Martinos Center for Biomedical Imaging, 149 13th St, Charlestown, MA, 02129, USA.
Recent progress in deep learning (DL) is producing a new generation of tools across numerous clinical applications. Within the analysis of brain tumors in magnetic resonance imaging, DL finds applications in tumor segmentation, quantification, and classification. It facilitates objective and reproducible measurements crucial for diagnosis, treatment planning, and disease monitoring.
View Article and Find Full Text PDFObjectives: To explore the impact of the SARS-CoV-2/COVID-19 pandemic on the diagnosis, management and patient journey for children and young people with a newly diagnosed brain tumour in the UK.
Design: Exploratory qualitative study focused on patient journeys from multiple perspectives, conducted as part of a wider mixed-methods study.
Setting: Three paediatric oncology tertiary centres in the UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!